Cytokines in liver health and disease

Liver Immunology: Principles and Practice

Volumn , Issue , 2007, Pages 83-93

  Invernizzi, Pietro ^a   Bianchi, Ilaria ^a   Locati, Massimo ^a,b   Bonecchi, Raffaella ^a,b   Selmi, Carlo ^a,c  

^a UNIVERSITY OF MILAN   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955748914     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-518-3_8     Document Type: Chapter

References (114)

1. Borish LC, Steinke JW. 2. Cytokines and chemokines. J Allergy Clin Immunol 2003; 111(2 Suppl):S460-S475
2. Bioulac-Sage P, Kuiper J, Van Berkel TJ, Balabaud C. Lymphocyte and macrophage populations in the liver. Hepatogastroenterology 1996; 43:4-14
3. Sheth K, Bankey P. The liver as an immune organ. Curr Opin Crit Care 2001; 7:99-104
4. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17:138-146
5. Hoyne GF, Lamb Jr. Peptide-mediated regulation of the allergic immune response. Immunol Cell Biol 1996; 74:180-186
6. Seder RA, Marth T, Sieve MC, et al. Factors involved in the differentiation of TGF-beta-producing cells from naive CD4+ T cells: IL- 4 and IFN-gamma have opposing effects, while TGF-beta positively regulates its own production. J Immunol 1998; 160:5719-5728
7. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16:34-38
8. Borchers MT, Wesselkamper S, Wert SE, Shapiro SD, Leikauf GD. Monocyte inflammation augments acrolein-induced Muc5ac expression in mouse lung. Am J Physiol 1999; 277:L489-L497
9. Roncarolo MG, Gregori S, Levings M. Type 1 T regulatory cells and their relationship with CD4+CD25+ T regulatory cells. Novartis Found Symp 2003; 252:115-127; discussion 27-31, 203-210
10. Kunkel SL. Through the looking glass: The diverse in vivo activities of chemokines. J Clin Invest 1999; 104:1333-1334
11. Rollins BJ. Chemokines. Blood 1997; 90:909-928
12. Zlotnik A, Yoshie O. Chemokines: A new classification system and their role in immunity. Immunity 2000; 12:121-127
13. Bone-Larson CL, Simpson KJ, Colletti LM, et al. The role of chemokines in the immunopathology of the liver. Immunol Rev 2000; 177:8-20
14. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998; 187:129-134
15. Locati M, Bonecchi R, Corsi MM. Chemokines and their receptors: Roles in specific clinical conditions and measurement in the clinical laboratory. Am J Clin Pathol 2005; 123 (Suppl):S82-S95
16. Shirasugi N, Wakabayashi G, Shimazu M, et al. Up-regulation of oxygen-derived free radicals by interleukin-1 in hepatic ischemia/ reperfusion injury. Transplantation 1997; 64:1398-1403
17. Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 2003; 14: 409-426
18. Moshage H. Cytokines and the hepatic acute phase response. J Pathol 1997; 181:257-266
19. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15:74-80
20. Kolesnick R, Golde DW. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 1994; 77:325-328
21. Ihle JN. STATs: Signal transducers and activators of transcription. Cell 1996; 84:331-334
22. Dinarello CA, Thompson RC. Blocking IL-1: Interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991; 12:404-410
23. Canbay A, Friedman S, Gores GJ. Apoptosis: The nexus of liver injury and fibrosis. Hepatology 2004; 39:273-278
24. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343:1467-1476
25. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001; 104: 487-501
26. Canbay A, Feldstein AE, Higuchi H, et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003; 38:1188-1198
27. Rust C, Gores GJ. Apoptosis and liver disease. Am J Med 2000; 108:567-574
28. Reddy SA, Chaturvedi MM, Darnay BG, Chan H, Higuchi M, Aggarwal BB. Reconstitution of nuclear factor kappa B activation induced by tumor necrosis factor requires membrane-associated components. Comparison with pathway activated by ceramide. J Biol Chem 1994; 269:25,369-25,372
29. Bissell DM, Roulot D, George J. Transforming growth factor beta and the liver. Hepatology 2001; 34:859-867
30. Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis 1999; 19:129-140
31. Eng FJ, Friedman SL, Fibrogenesis I. New insights into hepatic stellate cell activation: The simple becomes complex. Am J Physiol Gastrointest Liver Physiol 2000; 279:G7-G11
32. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001; 21:397-416
33. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. Hepatology 2006; 43(2 Suppl 1):S45-S53
34. Bode C, Bode JC. Activation of the innate immune system and alcoholic liver disease: Effects of ethanol per se or enhanced intestinal translocation of bacterial toxins induced by ethanol? Alcohol Clin Exp Res 2005; 29(11 Suppl):166S-171S.
35. Neuman MG. Cytokines - central factors in alcoholic liver disease. Alcohol Res Health 2003; 27:307-316
36. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218
37. Afford SC, Fisher NC, Neil DA, et al. Distinct patterns of chemokine expression are associated with leukocyte recruitment in alcoholic hepatitis and alcoholic cirrhosis. J Pathol 1998; 186: 82-89
38. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-2250
39. Prosser CC, Yen RD, Wu J. Molecular therapy for hepatic injury and fibrosis: Where are we? World J Gastroenterol 2006; 12: 509-515
40. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001; 21:373-384
41. Holmbeck K, Bianco P, Caterina J, et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999; 99:81-92
42. Marra F, Aleffi S, Bertolani C, Petrai I, Vizzutti F. Review article: The pathogenesis of fibrosis in non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2005; 22(Suppl 2):44-47
43. Valenti L, Fracanzani AL, Dongiovanni P, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 274-280
44. Bugianesi E, Zannoni C, Vanni E, Marzocchi R, Marchesini G. Nonalcoholic fatty liver and insulin resistance: A cause-effect relationship? Dig Liver Dis 2004; 36:165-173
45. Marra F. Leptin and liver fibrosis: A matter of fat. Gastroenterology 2002; 122:1529-1532
46. Cao Q, Mak KM, Ren C, Lieber CS. Leptin stimulates tissue inhibitor of metalloproteinase-1 in human hepatic stellate cells: Respective roles of the JAK/STAT and JAK-mediated H2O2-dependant MAPK pathways. J Biol Chem 2004; 279:4292-4304
47. Ikejima K, Takei Y, Honda H, et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002; 122:1399-1410
48. Bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology 2003; 38:4-13
49. Tseng CT, Miskovsky E, Houghton M, Klimpel GR. Characterization of liver T-cell receptor gammadelta T cells obtained from individuals chronically infected with hepatitis C virus (HCV): Evidence for these T cells playing a role in the liver pathology associated with HCV infections. Hepatology 2001; 33:1312-1320
50. Foster GR. Interferons in host defense. Semin Liver Dis 1997; 17:287-295
51. Rosen HR. Hepatitis C pathogenesis: Mechanisms of viral clearance and liver injury. Liver Transplant 2003; 9:S35-S43
52. Menne S, Roneker CA, Roggendorf M, Gerin JL, Cote PJ, Tennant BC. Deficiencies in the acute-phase cell-mediated immune response to viral antigens are associated with development of chronic woodchuck hepatitis virus infection following neonatal inoculation. J Virol 2002; 76:1769-1780
53. Sprengers D, Janssen HL. Immunomodulatory therapy for chronic hepatitis B virus infection. Fundam Clin Pharmacol 2005; 19: 17-26
54. Kakimi K, Lane TE, Chisari FV, Guidotti LG. Cutting edge: Inhibition of hepatitis B virus replication by activated NK T cells does not require inflammatory cell recruitment to the liver. J Immunol 2001; 167:6701-6705
55. Heise T, Guidotti LG, Cavanaugh VJ, Chisari FV. Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice. J Virol 1999; 73:474-481
56. Koziel MJ. Cytokines in viral hepatitis. Semin Liver Dis 1999; 19:157-169
57. Thimme R, Bukh J, Spangenberg HC, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 2002; 99:15,661-15,668
58. Kuzushita N, Hayashi N, Katayama K, et al. High levels of serum interleukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis C. Scand J Gastroenterol 1997; 32:169-174
59. Llorent L, Richaud-Patin Y, Alcocer-Castillejos N, et al. Cytokine gene expression in cirrhotic and non-cirrhotic human liver. J Hepatol 1996; 24:555-563
60. Crotta S, Stilla A, Wack A, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002; 195:35-41
61. Apolinario A, Majano PL, Alvarez-Perez E, et al. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: Relationship with the histological activity of liver disease. Am J Gastroenterol 2002; 97:2861-2870
62. Selmaj K, Raine CS, Farooq M, Norton WT, Brosnan CF. Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin. J Immunol 1991; 147:1522-1529
63. Foulis AK, McGill M, Farquharson MA. Insulitis in type 1 (insulin-dependent) diabetes mellitus in man - macrophages, lymphocytes, and interferon-gamma containing cells. J Pathol 1991; 165:97-103
64. Matthews N, Emery P, Pilling D, Akbar A, Salmon M. Subpopulations of primed T helper cells in rheumatoid arthritis. Arthritis Rheum 1993; 36:603-607
65. Harada K, Van de Water J, Leung PS, et al. In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: Predominance of the Th1 subset. Hepatology 1997; 25:791-796
66. Martinez OM, Villanueva JC, Gershwin ME, Krams SM. Cytokine patterns and cytotoxic mediators in primary biliary cirrhosis. Hepatology 1995; 21:113-119
67. Shindo M, Mullin GE, Braun-Elwert L, Bergasa NV, Jones EA, James SP. Cytokine mRNA expression in the liver of patients with primary biliary cirrhosis (PBC) and chronic hepatitis B (CHB). Clin Exp Immunol 1996; 105:254-259
68. Nagano T, Yamamoto K, Matsumoto S, et al. Cytokine profile in the liver of primary biliary cirrhosis. J Clin Immunol 1999; 19:422-427
69. Tjandra K, Sharkey KA, Swain MG. Progressive development of a Th1-type hepatic cytokine profile in rats with experimental cholangitis. Hepatology 2000; 31:280-290
70. Bo X, Broome U, Remberger M, Sumitran-Holgersson S. Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis. Gut 2001; 49:131-141
71. Spengler U, Moller A, Jung MC, et al. T lymphocytes from patients with primary biliary cirrhosis produce reduced amounts of lymphotoxin, tumor necrosis factor and interferon-gamma upon mitogen stimulation. J Hepatol 1992; 15:129-135
72. Spirli C, Fabris L, Duner E, et al. Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology 2003; 124:737-753
73. Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis 2002; 6:727-737
74. Tanaka Y, Takahashi A, Watanabe K, et al. A pivotal role of IL-12 in Th1-dependent mouse liver injury. Int Immunol 1996; 8:569-576
75. Nicoletti F, Di Marco R, Zaccone P, et al. Murine concanavalin A-induced hepatitis is prevented by interleukin 12 (IL-12) antibody and exacerbated by exogenous IL-12 through an interferon-gammadependent mechanism. Hepatology 2000; 32:728-733
76. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: New players in the regulation of T cell responses. Immunity 2003; 19:641-644
77. Humar A, Kosari K, Sielaff TD, et al. Liver regeneration after adult living donor and deceased donor split-liver transplants. Liver Transplant 2004; 10:374-378
78. Iwai M, Cui TX, Kitamura H, Saito M, Shimazu T. Increased secretion of tumour necrosis factor and interleukin 6 from isolated, perfused liver of rats after partial hepatectomy. Cytokine 2001; 13:60-64
79. Serandour AL, Loyer P, Garnier D, et al. TNFalpha-mediated extracellular matrix remodeling is required for multiple division cycles in rat hepatocytes. Hepatology 2005; 41:478-486
80. Blindenbacher A, Wang X, Langer I, Savino R, Terracciano L, Heim MH. Interleukin 6 is important for survival after partial hepatectomy in mice. Hepatology 2003; 38:674-682
81. Lentsch AB, Kato A, Yoshidome H, McMasters KM, Edwards MJ. Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury. Hepatology 2000; 32: 169-173
82. Boros P, Bromberg JS. New cellular and molecular immune pathways in ischemia/reperfusion injury. Am J Transplant 2006; 6:652-658
83. Colletti LM, Kunkel SL, Walz A, et al. Chemokine expression during hepatic ischemia/reperfusion-induced lung injury in the rat. The role of epithelial neutrophil activating protein. J Clin Invest 1995; 95:134-141
84. Lentsch AB, Yoshidome H, Kato A, et al. Requirement for interleukin- 12 in the pathogenesis of warm hepatic ischemia/reperfusion injury in mice. Hepatology 1999; 30:1448-1453
85. Yoshidome H, Kato A, Edwards MJ, Lentsch AB. Interleukin-10 suppresses hepatic ischemia/reperfusion injury in mice: Implications of a central role for nuclear factor kappaB. Hepatology 1999; 30: 203-208
86. Huang YS, Chan CY, Wu JC, Pai CH, Chao Y, Lee SD. Serum levels of interleukin-8 in alcoholic liver disease: Relationship with disease stage, biochemical parameters and survival. J Hepatol 1996; 24:377-384
87. Uguccioni M, Meliconi R, Nesci S, et al. Elevated interleukin-8 serum concentrations in beta-thalassemia and graft-versus-host disease. Blood 1993; 81:2252-2256
88. Zhang P, Xie M, Zagorski J, Spitzer JA. Attenuation of hepatic neutrophil sequestration by anti-CINC antibody in endotoxic rats. Shock 1995; 4:262-268
89. Colletti LM, Green M, Burdick MD, Kunkel SL, Strieter RM. Proliferative effects of CXC chemokines in rat hepatocytes in vitro and in vivo. Shock 1998; 10:248-257
90. Mercer-Jones MA, Shrotri MS, Peyton JC, Remick DG, Cheadle WG. Neutrophil sequestration in liver and lung is differentially regulated by C-X-C chemokines during experimental peritonitis. Inflammation 1999; 23:305-319
91. Lentsch AB, Yoshidome H, Cheadle WG, Miller FN, Edwards MJ. Chemokine involvement in hepatic ischemia/reperfusion injury in mice: Roles for macrophage inflammatory protein-2 and KC. Hepatology 1998; 27:1172-1177
92. Tilg H, Ceska M, Vogel W, Herold M, Margreiter R, Huber C. Interleukin-8 serum concentrations after liver transplantation. Transplantation 1992; 53:800-803
93. Nanji AA, Jokelainen K, Rahemtulla A, et al. Activation of nuclear factor kappa B and cytokine imbalance in experimental alcoholic liver disease in the rat. Hepatology 1999; 30:934-943
94. Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol 1999; 163:6236-6243
95. Yoong KF, Afford SC, Jones R, et al. Expression and function of CXC and CC chemokines in human malignant liver tumors: A role for human monokine induced by gamma-interferon in lymphocyte recruitment to hepatocellular carcinoma. Hepatology 1999; 30: 100-111
96. Goddard S, Williams A, Morland C, et al. Differential expression of chemokines and chemokine receptors shapes the inflammatory response in rejecting human liver transplants. Transplantation 2001; 72:1957-1967
97. Shibuta K, Begum NA, Mori M, Shimoda K, Akiyoshi T, Barnard GF. Reduced expression of the CXC chemokine hIRH/SDF-1alpha mRNA in hepatoma and digestive tract cancer. Int J Cancer 1997; 73:656-662
98. Narumi S, Tominaga Y, Tamaru M, et al. Expression of IFN-inducible protein-10 in chronic hepatitis. J Immunol 1997; 158:5536-5544
99. Marra F, DeFranco R, Grappone C, et al. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: Correlation with monocyte infiltration. Am J Pathol 1998; 152: 423-430
100. Salkowski CA, Detore G, Franks A, Falk MC, Vogel SN. Pulmonary and hepatic gene expression following cecal ligation and puncture: Monophosphoryl lipid A prophylaxis attenuates sepsis-induced cytokine and chemokine expression and neutrophil infiltration. Infect Immun 1998; 66:3569-3578
101. Murai M, Yoneyama H, Harada A, et al. Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest 1999; 104: 49-57
102. Adams DH, Hubscher S, Fear J, Johnston J, Shaw S, Afford S. Hepatic expression of macrophage inflammatory protein-1 alpha and macrophage inflammatory protein-1 beta after liver transplantation. Transplantation 1996; 61:817-825
103. Salazar-Mather TP, Orange JS, Biron CA. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1alpha (MIP-1alpha)-dependent pathways. J Exp Med 1998; 187:1-14
104. Fisher NC, Neil DA, Williams A, Adams DH. Serum concentrations and peripheral secretion of the beta chemokines monocyte chemoattractant protein 1 and macrophage inflammatory protein 1alpha in alcoholic liver disease. Gut 1999; 45:416-420
105. Hirano F, Kobayashi A, Hirano Y, Nomura Y, Fukawa E, Makino I. Bile acids regulate RANTES gene expression through its cognate NF-kappaB binding sites. Biochem Biophys Res Commun 2001; 288:1095-1101
106. Kusano F, Tanaka Y, Marumo F, Sato C. Expression of C-C chemokines is associated with portal and periportal inflammation in the liver of patients with chronic hepatitis C. Lab Invest 2000; 80:415-422
107. Muruve DA, Barnes MJ, Stillman IE, Libermann TA. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 1999; 10:965-976
108. Nagral A, Ben-Ari Z, Dhillon AP, Burroughs AK. Eosinophils in acute cellular rejection in liver allografts. Liver Transplant Surg 1998; 4:355-362
109. Pham BN, Bemuau J, Durand F, et al. Eotaxin expression and eosinophil infiltrate in the liver of patients with drug-induced liver disease. J Hepatol 2001; 34:537-547
110. Yoneyama H, Harada A, Imai T, et al. Pivotal role of TARC, a CC chemokine, in bacteria-induced fulminant hepatic failure in mice. J Clin Invest 1998; 102:1933-1941
111. Chvatchko Y, Hoogewerf AJ, Meyer A, et al. A key role for CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock. J Exp Med 2000; 191:1755-1764
112. Matsukawa A, Kaplan MH, Hogaboam CM, Lukacs NW, Kunkel SL. Pivotal role of signal transducer and activator of transcription (Stat)4 and Stat6 in the innate immune response during sepsis. J Exp Med 2001; 193:679-688
113. Shimizu Y, Murata H, Kashii Y, et al. CC-chemokine receptor 6 and its ligand macrophage inflammatory protein 3alpha might be involved in the amplification of local necroinflammatory response in the liver. Hepatology 2001; 34:311-319
114. Simpson KJ, Henderson NC, Bone-Larson CL, Lukacs NW, Hogaboam CM, Kunkel SL. Chemokines in the pathogenesis of liver disease: So many players with poorly defined roles. Clin Sci (Lond) 2003; 104:47-63